QNRXManagement•globenewswire•
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
Sentiment:Negative (20)
Summary
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 18, 2025 by globenewswire